1. Gilead says remdesivir cut risk of COVID patient death in clinical trial — BioNTech-Pfizer COVID vaccine expected to be ready for approval by year end — LEO Pharma eyeing 2021 launch for Dupixent rival — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Valeant's Progress Towards Paying Down $5Bil Debt

Discussion in 'Valeant Pharmaceuticals' started by RobertPhillips900, Oct 10, 2017 at 12:49 PM.

  1. RobertPhillips900

    Joined:
    Aug 29, 2016
    Messages:
    51
    Likes Received:
    0
    Is Valeant is making a good progress towards paying down a huge debt of $5Bil Debt by Feb. 2018?
    Take a look at their progress. http://alph.st/bd2f993b
     

  2. anonymous

    anonymous Guest

    No real progress, the iNova proceeds have been accounted for already. They will probably pay down existing debt with new longer term debt at higher interest rates, basically kicking the can down the road. This strategy has worked for the US government so far, why shouldn't it work for Valeant? It didn't work for Greece, but the banks have been playing ball with Valeant. They may issue equity, which will dilute existing shareholders, but they should have done that when the stock was at 250/share, not 14. Had they done that, the share price would probably still be in the triple digits.